CV6 Therapeutics

CV6 Therapeutics is a biotechnology company developing investigational therapies designed for combination use with established standards of care in oncology and inflammatory diseases. Its lead candidate, CV6-168, is a dHFTase inhibitor currently in Phase 1a clinical trials intended to enhance the efficacy of thymidylate synthase-targeted therapies like 5-fluorouracil. The company's approach focuses on inducing DNA repair stress responses and stimulating innate immune signaling to treat major cancers including colorectal, breast, and lung cancer.